Interestingly, pharmacological inhibition of survivin using the small molecule YM155, either as a single agent or in combination with cisplatin, evidenced a significant dose-dependent decrease in cell proliferation and the reversion of cisplatin resistance in in vitro and in vivo models of HNSCC. The gene discussed is BIRC5; the disease is head and neck squamous cell carcinoma.